STOCK TITAN
  1. Home
  2. Sec-filings
  3. ALLO
  4. [8-K] Allogene Therapeutics, Inc. Reports Material Event

Allogene Therapeutics, Inc. reported $0 in revenue and a $190.9M net loss for fiscal 2025. See the full ALLO financial statements: income statement, balance sheet, cash flow and ratios, each column linked to its SEC filing.

Allogene Therapeutics CFO to retire in 2026

Allogene Therapeutics, Inc. (ALLO) announced that Geoffrey Parker, its Executive Vice President, Chief Financial Officer and principal financial officer, has notified the company of his retirement from all positions.

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
8-K

Rhea-AI Filing Summary

Allogene Therapeutics, Inc. (ALLO) announced that Geoffrey Parker, its Executive Vice President, Chief Financial Officer and principal financial officer, has notified the company of his retirement from all positions. His retirement will be effective November 6, 2026, following notice given on August 31, 2026. The report is signed by President and Chief Executive Officer Zachary Roberts, M.D., Ph.D.

Positive

  • None.

Negative

  • Planned retirement of CFO and principal financial officer Geoffrey Parker, effective November 6, 2026, introduces senior leadership transition risk in the company’s finance function.
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance
Key personnel changes including departures, elections, or appointments of directors and executive officers.
Retirement effective date November 6, 2026 Effective date of Geoffrey Parker’s retirement from all capacities
Retirement notice date August 31, 2026 Date Geoffrey Parker provided notice of retirement
Common Stock par value $0.001 per share Par value of Allogene Therapeutics, Inc. common stock
principal financial officer financial
"Executive Vice President and Chief Financial Officer and principal financial officer"
The principal financial officer is the senior executive who runs a company's financial operations: preparing and certifying financial reports, managing accounting controls, budgets and cash flow, and advising on financial strategy. Investors care about this role because its competence affects how trustworthy the company’s numbers are, how well it manages risk and capital needs, and the credibility of forecasts—like the chief navigator steering a firm's financial course.
Emerging growth company regulatory
"Emerging growth company    (b) On August 31, 2026"
An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.
Securities Exchange Act of 1934 regulatory
"Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934"

FAQ

What executive change did Allogene Therapeutics (ALLO) disclose on August 31, 2026?
Allogene Therapeutics disclosed that Geoffrey Parker, Executive Vice President, Chief Financial Officer and principal financial officer, provided notice of his retirement from all roles on August 31, 2026, with an effective retirement date of November 6, 2026.

When will Allogene Therapeutics’ CFO Geoffrey Parker retire?
Geoffrey Parker’s retirement from Allogene Therapeutics as Executive Vice President, Chief Financial Officer and principal financial officer will be effective on November 6, 2026, following his notice given on August 31, 2026.

What roles does Geoffrey Parker hold at Allogene Therapeutics (ALLO)?
Geoffrey Parker serves as Executive Vice President, Chief Financial Officer, and principal financial officer of Allogene Therapeutics, Inc. He has notified the company of his retirement from all these capacities, effective November 6, 2026.

Who signed the Allogene Therapeutics (ALLO) report announcing the CFO’s retirement?
The report announcing Geoffrey Parker’s planned retirement was signed by Zachary Roberts, M.D., Ph.D., who is the President and Chief Executive Officer of Allogene Therapeutics, Inc.

On which exchange is Allogene Therapeutics (ALLO) common stock listed?
Allogene Therapeutics’ common stock, par value $0.001 per share, trades under the symbol ALLO on The Nasdaq Stock Market LLC.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
false 0001737287 0001737287 2026-08-31 2026-08-31
 
 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 31, 2026

 

 

Allogene Therapeutics, Inc.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   001-38693   82-3562771

(State or other jurisdiction

of incorporation)

  

(Commission

File Number)

  

(I.R.S. Employer

Identification No.)

210 East Grand Avenue, South San Francisco, California 94080

(Address of principal executive offices including zip code)

Registrant’s telephone number, including area code: (650) 457-2700

 

(Former name or former address, if changed since last report.)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

  ☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

  ☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

  ☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

  ☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

  

Trading
Symbol(s)

  

Name of each exchange

on which registered

Common Stock, $0.001 par value per share   ALLO   The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 
 

Item 5.02

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

(b)

On August 31, 2026, Geoffrey Parker, the Executive Vice President and Chief Financial Officer and principal financial officer of Allogene Therapeutics, Inc. (the “Company”), provided notice of his retirement from the Company in all capacities, effective November 6, 2026.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

ALLOGENE THERAPEUTICS, INC.
By:  

/s/ Zachary Roberts

  Zachary Roberts, M.D., Ph.D.
  President and Chief Executive Officer

Dated: September 2, 2026

Source: View Original Filing on SEC EDGAR

Filing Exhibits & Attachments

3 documents

Other Documents